S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
NASDAQ:FIXX

Homology Medicines Stock Forecast, Price & News

$5.05
-0.12 (-2.32%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.01
$5.28
50-Day Range
$5.05
$8.71
52-Week Range
$4.99
$15.24
Volume
874,807 shs
Average Volume
523,358 shs
Market Capitalization
$288.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.55
30 days | 90 days | 365 days | Advanced Chart
Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.


Homology Medicines logo

About Homology Medicines

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing, and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Headlines

Homology Medicines (NASDAQ:FIXX) Price Target Cut to $25.00
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
205
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.70 million
Book Value
$4.33 per share

Profitability

Net Income
$-128.69 million
Net Margins
-269.33%
Pretax Margin
-269.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,748,000
Market Cap
$288.61 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

316th out of 1,390 stocks

Pharmaceutical Preparations Industry

140th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

Is Homology Medicines a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Homology Medicines stock.
View analyst ratings for Homology Medicines
or view top-rated stocks.

How has Homology Medicines' stock price been impacted by Coronavirus?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FIXX shares have decreased by 71.8% and is now trading at $5.05.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Homology Medicines?

Homology Medicines saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 3,360,000 shares, an increase of 41.8% from the October 14th total of 2,370,000 shares. Based on an average daily volume of 478,700 shares, the days-to-cover ratio is currently 7.0 days. Currently, 8.4% of the shares of the stock are sold short.
View Homology Medicines' Short Interest
.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Homology Medicines
.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.60) by $0.06. Homology Medicines had a negative net margin of 269.33% and a negative trailing twelve-month return on equity of 44.87%.
View Homology Medicines' earnings history
.

What price target have analysts set for FIXX?

5 equities research analysts have issued 1 year price targets for Homology Medicines' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate Homology Medicines' stock price to reach $22.40 in the next twelve months. This suggests a possible upside of 343.6% from the stock's current price.
View analysts' price targets for Homology Medicines
or view top-rated stocks among Wall Street analysts.

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Arthur O. Tzianabos, President, Chief Executive Officer & Director
  • Timothy P. Kelly, Chief Operating Officer (LinkedIn Profile)
  • W. Bradford Smith, Chief Financial Officer, Secretary & Treasurer
  • Albert Seymour, Chief Scientific Officer
  • Gabriel M. Cohn, Chief Medical Officer

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), (CGC) and Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Temasek Holdings Private Ltd (9.90%), BlackRock Inc. (6.08%), Wellington Management Group LLP (1.37%), Geode Capital Management LLC (1.26%), Goldman Sachs Group Inc. (0.45%) and Two Sigma Investments LP (0.28%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Timothy P Kelly, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends for Homology Medicines
.

Which institutional investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Millennium Management LLC, Morgan Stanley, GSA Capital Partners LLP, Citadel Advisors LLC, AAF Wealth Management LLC, Dupont Capital Management Corp, and Alliancebernstein L.P.. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Kush Parmar, and Timothy P Kelly.
View insider buying and selling activity for Homology Medicines
or view top insider-selling stocks.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was acquired by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Two Sigma Investments LP, BlackRock Inc., Panagora Asset Management Inc., Dimensional Fund Advisors LP, Franklin Resources Inc., SG Americas Securities LLC, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for Homology Medicines
or or view top insider-buying stocks.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $5.05.

How much money does Homology Medicines make?

Homology Medicines has a market capitalization of $288.61 million and generates $2.70 million in revenue each year. The company earns $-128.69 million in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Homology Medicines have?

Homology Medicines employs 205 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

Where are Homology Medicines' headquarters?

Homology Medicines is headquartered at ONE PATRIOTS PARK, BEDFORD MA, 01730.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at (781) 301-7277.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.